RIGL - 2.50 Pre-market at 2.84/2.90 Rigel Announces NIH/NHLBI-Sponsored Trial Of Fostamatinib In Hospitalized COVID-19 Patients In Collaboration With Inova https://stockcharts.com/h-sc/ui?s=rigl